Cannabinoids modulate pain by multiple mechanisms of action

Journal of Pain

Volumn 1, Issue 1, 2000, Pages 2-14

  Richardson, Jennelle Durnett ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Analgesia; Cannabinoid; Endogenous; Hyperalgesia; Nociception

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANALGESIC AGENT; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; LEVONANTRADOL; MORPHINE; NABILONE; OPIATE DERIVATIVE; RIMONABANT;

ANALGESIC ACTIVITY; ANTINOCICEPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPERALGESIA; NEUROMODULATION; NOCICEPTION; PAIN THRESHOLD; REVIEW;

EID: 0033884835     PISSN: 15265900     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-5900(00)90082-8     Document Type: Article

References (118)

1. Extensive pulmonary haemorrhage in an Egyptian mummy
2. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking
3. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial
4. The analgesic properties of delta-9-tetrahydrocannabinol and codeine
5. The perceived effects of smoked cannabis on patients with multiple sclerosis
6. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain
7. Nabilone in the treatment of multiple sclerosis
8. Isolation, structure, and partial synthesis of an active constituent of hashish
9. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
10. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
11. A second endogenous cannabinoid that modulates long-term potentiation
12. 2-Arachidonylglycerol: A possible endogenous cannabinoid receptor ligand in brain
13. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells
14. Transacylase-mediated and phophodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand in rat brain microsomes
15. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells
16. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP
17. 2+-dependent transacylase and phosphodiesterase activities
18. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
19. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
20. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion
21. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
22. Anandamide amidohydrolase activity in rat brain microsomes
23. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
24. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand
25. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain
26. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide
27. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
28. Molecular cloning of a human cannabinoid receptor which is also expressed in testis
29. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
30. Molecular characterization of a peripheral receptor for cannabinoids
31. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
32. The peripheral cannabinoid receptor: Adenylate cyclase inhibition of G protein coupling
33. 2 receptors
34. Cannabinoid inhibition of adenylate cylcase: Pharmacology of the response in neuroblastoma cell membranes
35. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
36. 2+ current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism
37. Cannabinoids modulate potassium current in cultured hippocampal neurons
38. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes
39. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells
40. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor
41. 2+ channels in a neuronal expression system
42. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide
43. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
44. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
45. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1
46. Control of pain initiation by endogenous cannabinoids
47. 9-tetrahydrocannabinol-induced responses and apparent agonist activity
48. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus
49. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR 141716A
50. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
51. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55,212-2, and is potentiated by the cannabinoid antagonist, SR 141716A
52. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices
53. 9 dopamine neuronal activity in the rat
54. The analgesic effects of R(+)-WlN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
55. 1 receptor
56. 1 receptor
57. 2 receptors
58. An analgesia circuit activated by cannabinoids
59. 1 cannabinoid receptor activity
60. 1 receptors in guinea-pig small intestine
61. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist
62. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
63. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia
64. Cannabinoid receptor-mediated inhibition of dopamine release in the retina
65. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
66. 1 cannabinoid receptor antagonist, SR 141716A
67. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
68. 2 cannabinoid receptor
69. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects
70. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2
71. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat
72. Cannabinoid receptors undergo axonal flow in sensory nerves
73. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study
74. Anti-hyperalgesic effects of spinal cannabinoids
75. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment
76. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
77. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
78. 1 receptors in the rat central nervous system
79. An examination of the central sites of action of cannabinoid-induced antinociception in the rat
80. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog
81. Spinal and supraspinal components of cannabinoid-induced antinociception
82. 9-tetrahydrocannabinol-induced analgesia
83. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2
84. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
85. 2-noradrenergic mechanism
86. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord
87. 9-tetrahydrocannabinol and morphine in the spinal cord
88. 9-tetrahydrocannabinol-induced analgesia in mice
89. 9-tetrahydrocannabinol-induced antinociception in mice
90. 9-tetrahydrocannabinol and kappa opioids in mice
91. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not n,n-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice
92. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after micro-injection into the rostral ventralmedial medulla
93. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
94. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
95. 1 receptors
96. Intraplantar injection of the cannabinoid receptor agonist CP 55,940 attenuates capsaicin-evoked nocifensive behavior and hyperalgesia in rats
97. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
98. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat
99. 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats
100. Analgesic, respiratory, and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A
101. 1 receptor knockout mice
102. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice
103. Modulation of rat brain opioid receptors by cannabinoids
104. 9-tetrahydrocannabinol in the mouse
105. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of μ and κ-opioid receptors
106. 1-13, and a kappa-receptor agonist U50,488
107. Levonantradoh: A role for central prostanoid mechanism?
108. 9-THC)
109. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
110. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
111. Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol
112. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement
113. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats
114. Antinociceptive actions of cannabinoids following intraventricular administration in rats
115. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat
116. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol
117. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice